Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

Centre, University College London. "These data indicate BIBF 1120 may have a potential role in delaying disease progression in patients with ovarian cancer who had previously responded to chemotherapy."(11)

Because angiogenesis plays a pivotal role in the growth of solid tumors,(13) BIBF 1120 is currently being investigated in a number of cancer types including advanced NSCLC. The LUME-Lung Phase III clinical trial program is investigating BIBF 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC. Approximately 2,600 patients will be enrolled, making this one of the largest Phase III study programs in this NSCLC patient population to date.

About Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer.(3,14) In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).(18)

About Ovarian Cancer

According to the 2008 World Health Organization World Cancer Report, as of 2002, ovarian cancer was ranked as the 6th most common cancer in women. Additionally, approximately 204,000 new cases were diagnosed worldwide and 125,000 women died from the disease in 2002.(14) The ACS estimates that about 21,650 new cases of ovarian cancer were diagnosed in the United States (U.S.) during 2008. Only forty-five percent of women with ovarian cancer are still alive at least five years after diagnosis in the U.S.(19)

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... today announced that Tom Ryan , Chairman, President and CEO, and Per Lofberg , Executive Vice President ... Healthcare Conference on March 23, 2010 . The Company is scheduled to speak at approximately 9:00 a.m. ... ... , , ...
... Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced today that it ... June 3, 2010 , in Rockville, Maryland .  The record ... .  Only stockholders of record at the close of business on ... any adjournment thereof.  Vanda anticipates mailing its proxy statement in ...
Cached Medicine Technology:CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 2CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 3Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders 2
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... 12 June 2009: After five years of receiving infliximab ... (AS) showed substantial clinical benefit (ASAS40, ASsessment in AS, ... five years, 78.4% of AS patients had no arthritis ... between tendon and bone). Over this period, patients continued ...
... The board of directors of Abbott today declared a quarterly common dividend ... 342nd consecutive quarterly dividend to be paid by Abbott since 1924. ... at the close of business on July 15, 2009. , , ... an 11 percent increase earlier this year - and was again named ...
... CHICAGO, June 12 Germany remains an attractive investment,location ... states.,This is in large part due to the robust ... American investor interest in,Germany remains steady, as confirmed by ... success stories at the "How,Far East? Eastern Germany: The ...
... Medifast, Inc. (NYSE: MED ) today announced that ... Medifast Weight Control Centers. Earlier in the year, the Company ... and analyze the success of the model throughout the year. ... expanding its investment in this area. , , Despite ...
... Travelers Turn to InsureMyTrip.com for Coverage Protection and Information ... ,the scientific criteria for an influenza pandemic have been ... the A(H1N1) virus, commonly referred to as Swine Flu, ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ) , , "Particularly in ...
... of the University of Southern California (USC) have identified ... to breakan occurrence that marks the first step in ... researchers with the clearest insight yet into why these ... chromosome, says principal investigator Michael R. Lieber, M.D., Ph.D., ...
Cached Medicine News:Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:American Investors Highlight Successes in Eastern Germany 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 3Health News:World Health Organization Declares A(H1N1) Pandemic 2Health News:World Health Organization Declares A(H1N1) Pandemic 3Health News:USC researchers identify DNA mutation that occurs at beginning point of T-cell lymphoma 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 11.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 6 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 7 mm....
Medicine Products: